<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02407197</url>
  </required_header>
  <id_info>
    <org_study_id>2011-T1-MC</org_study_id>
    <nct_id>NCT02407197</nct_id>
  </id_info>
  <brief_title>International T1 Multicentre CMR Outcome Study in Patients With Nonischaemic Cardiomyopathies</brief_title>
  <acronym>T1-CMR</acronym>
  <official_title>International T1 Multicentre CMR Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myocardial fibrosis is the fundamental substrate for the development of heart failure.

      Cardiovascular magnetic resonance (CMR) allows non-invasive assessment of myocardial fibrosis
      based on late gadolinium enhancement (LGE) and T1 mapping.

      Patients: Prospective longitudinal observational multicenter study of consecutive patients
      with suspected or known non-ischemic cardiomyopathy.

      Imaging: Non-invasive measures of myocardial fibrosis: native T1, extracellular volume
      fraction (ECV) and LGE.

      Primary endpoints: all cause and cardiovascular mortality.

      Secondary endpoints: arrhythmic composite and HF composite endpoints.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>1 year</time_frame>
    <description>all cause mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>1 year</time_frame>
    <description>composite of sudden cardiac death (SCD), death from HF, death from stroke or thromboembolic event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arrhythmic composite endpoint</measure>
    <time_frame>1 year</time_frame>
    <description>fatal or aborted SCD (including a documented appropriate shock from ICD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HF composite end point</measure>
    <time_frame>1 year</time_frame>
    <description>HF death and unplanned HF hospitalization</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Cardiomyopathy</condition>
  <condition>Heart Failure</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients fulfilling criteria of NICM in the absence of CAD and/or infarct-type LGE OR
        Subjects with high pretest probability for cardiomyopathy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients fulfilling the criteria of NICM OR

          -  presence of structural heart disease OR

          -  exhibiting myocardial LGE in non-ischemic pattern of LGE on CMR OR

          -  subjects with high pretest probability for cardiomyopathy

          -  persistent symptoms

          -  comorbidities

          -  first degree relative of a patient with known cardiomyopathy

          -  family history of sudden cardiac death (SCD)

        Exclusion Criteria:

          -  known or suspected myocardial infiltration due to amyloidosis, iron accumulation,
             lipid-storage disease or edema due to active myocardial inflammation

          -  known ischemic heart disease (IHD) based on at least one of the following: significant
             documented coronary artery disease (CAD), previous coronary revascularization,
             previous a history of myocardial infarction, or evidence of ischemic type-LGE or
             significant inducible ischemia on CMR

          -  history of renal disease with a current eGFR&lt;30 mL/min/1.73m2

          -  signifact structural valvular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eike Nagel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valentina Puentmann, MD, PhD</last_name>
    <phone>+447881943320</phone>
    <email>valentina.puntmann@kgu.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vincent's University</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>NSW 2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Jabbour, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>German Heart Institute Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rolf Gebker, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guy's and St. Thomas' Hospital Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Dabir D, Child N, Kalra A, Rogers T, Gebker R, Jabbour A, Plein S, Yu CY, Otton J, Kidambi A, McDiarmid A, Broadbent D, Higgins DM, Schnackenburg B, Foote L, Cummins C, Nagel E, Puntmann VO. Reference values for healthy human myocardium using a T1 mapping methodology: results from the International T1 Multicenter cardiovascular magnetic resonance study. J Cardiovasc Magn Reson. 2014 Oct 21;16:69. doi: 10.1186/s12968-014-0069-x.</citation>
    <PMID>25384607</PMID>
  </reference>
  <reference>
    <citation>Hinojar R, Foote L, Arroyo Ucar E, Jackson T, Jabbour A, Yu CY, McCrohon J, Higgins DM, Carr-White G, Mayr M, Nagel E, Puntmann VO. Native T1 in discrimination of acute and convalescent stages in patients with clinical diagnosis of myocarditis: a proposed diagnostic algorithm using CMR. JACC Cardiovasc Imaging. 2015 Jan;8(1):37-46. doi: 10.1016/j.jcmg.2014.07.016. Epub 2014 Dec 10.</citation>
    <PMID>25499131</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2015</study_first_submitted>
  <study_first_submitted_qc>March 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2015</study_first_posted>
  <last_update_submitted>March 30, 2015</last_update_submitted>
  <last_update_submitted_qc>March 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King's College London</investigator_affiliation>
    <investigator_full_name>Eike Nagel</investigator_full_name>
    <investigator_title>Global Chief Investigator</investigator_title>
  </responsible_party>
  <keyword>T1 mapping</keyword>
  <keyword>CMR</keyword>
  <keyword>Outcome</keyword>
  <keyword>multicenter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

